Evidence map›Paper›PMID 32078469›Full record

Trial reportJournal of applied physiology (Bethesda, Md. : 1985)2020

Effect of acetazolamide on susceptibility to central sleep apnea in chronic spinal cord injury.

Geoffrey Ginter, Abdulghani Sankari, Mehdi Eshraghi, Harold Obiakor, Hossein Yarandi, Susmita Chowdhuri, Anan Salloum, M Safwan Badr

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of applied physiology (Bethesda, Md. : 1985), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 3 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pharmacological treatment for central sleep apnoea in adults.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Pooled it
  3. The role of acetazolamide in sleep apnea at sea level: a systematic review and meta-analysis.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2021
    Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Geoffrey GinterJohn D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.
Abdulghani SankariJohn D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.ORCID 0000-0002-2400-3375
Mehdi EshraghiJohn D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.
Harold ObiakorJohn D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.
Hossein YarandiWayne State University, Detroit, Michigan.
Susmita ChowdhuriJohn D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.
Anan SalloumJohn D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.
M Safwan BadrJohn D. Dingell Veterans Affairs Medical Center, Detroit, Michigan.
Wayne State University · US

Funding

Sleep-Disordered Breathing in patients with C-SCI: Mechanisms and TherapyR01HL130552 · NHLBI · WAYNE STATE UNIVERSITY · PI BADR, M.SAFWAN · 2016 to 2020
$1.5M
Sleep and Breathing in Patients With Spinal Cord InjuryI01CX001040 · VA · JOHN D DINGELL VA MEDICAL CENTER · PI BADR, M.SAFWAN · 2014 to 2017
–
CSRD VA I01 CX001040CSRD VA IK2 CX000547NHLBI NIH HHS R01 HL130552
6 · The paper itself

Abstract

Spinal cord injury (SCI) is an established risk factor for central sleep apnea. Acetazolamide (ACZ), a carbonic anhydrase inhibitor, has been shown to decrease the frequency of central apnea by inducing mild metabolic acidosis. We hypothesized that ACZ would decrease the propensity to develop hypocapnic central apnea and decrease the apneic threshold. We randomized 16 participants with sleep-disordered breathing (8 SCI and 8 able-bodied controls) to receive ACZ (500 mg twice a day for 3 days) or placebo with a 1-wk washout before crossing over to the other drug arm. Study nights included polysomnography and determination of the hypocapnic apneic threshold and CO

Indexed as

Sleep Apnea, CentralSpinal Cord InjuriesAcetazolamideCarbon DioxideHumansPolysomnographyAcetazolamideCarbon Dioxideacetazolamidecentral sleep apnealoop gainspinal cord injury

Identifiers

PMID32078469
PMCPMC7191512
OpenAlexW3008401116

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.